Navigation Links
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
Date:7/30/2009

MONMOUTH JUNCTION, N.J., July 30 /PRNewswire/ -- Transave Inc. announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study ARIKACE(TM) (liposomal amikacin for inhalation) in patients with nontuberculous mycobacteria (NTM) lung infections.

Transave and NIAID will collaborate on the planning, design and implementation of a clinical trial to evaluate ARIKACE in patients with NTM lung disease who have failed to respond to standard, guideline-based treatment regimens. The study will assess the safety and tolerability of ARIKACE versus placebo administered once daily for several continuous months using an investigational eFlow(R) Nebulizer System (PARI Pharma GmbH), a novel, highly efficient and portable aerosol delivery system. About 35 patients will be enrolled in the trial to be conducted at the NIH Clinical Center in Bethesda, MD.

"This is the third type of chronic lung infection for which ARIKACE is being evaluated," said Tim Whitten, chief executive officer of Transave. "The preliminary success with ARIKACE demonstrating a sustained clinical benefit in treating cystic fibrosis (CF) patients with Pseudomonas lung infections is encouraging as we tackle this additional disease state in collaboration with NIAID."

There is no clear evidence on what triggers NTM disease, but the bacteria are commonly found in potable water and in soil, and it has been associated with lung disease in certain patients. Transave estimates that there are at least 30,000 patients suffering with NTM lung disease in the United States. Current treatment requires lengthy multi-drug regimens that are often poorly tolerated and not very effective, especially in patients with severe disease or in those who have failed prior treatments
'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transave, Inc. Secures $12.5 Million in New Financing
2. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
3. Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
4. NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling
5. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
6. The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding
7. Delcath Enters Agreement to Sell 869,565 Units
8. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
9. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
10. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
11. Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... among stations to run 30-second spot on Pyratine XR(TM) and ... Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company ... of healthy aging, announced today that on June 27, 2009 ... XR(TM) (0.125% furfuryl tetrahydropyranyl adenine) and rosacea, a condition afflicting ...
... N.C., June 26 Syngenta Biotechnology, Inc. announced today ... and commercial license agreement for Chromatin,s proprietary gene stacking ... Chromatin has developed a novel approach to gene stacking, ... Under this agreement, Syngenta has obtained exclusive rights to ...
... EasyMax™ is a ... heating and cooling without an additional cryostat. For a limited time, METTLER TOLEDO is ... EasyMax™, and the chance to WIN A SKI WEEKEND* in St. Moritz, Switzerland or Colorado, ... Columbia, MD (PRWEB) ...
Cached Biology Technology:Television News Segment Featuring Pyratine XR to Air to 18 Million + Households on DIRECTV NewsCluster 2Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane 2Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane 3Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training 2
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... accumulation of genetic damage in our cells is a major ... published today in the journal Nature by an international group ... critical gene for repairing damaged DNA grow old rapidly and ... that grow old naturally. Furthermore, the premature aging symptoms of ...
... transplant (HSCT) recipients face a significant long-term risk for ... at the time of transplant or received stem cells ... Published in the January 1, 2007 issue of CANCER ... Cancer Society, the study reveals that within 10 years ...
... researchers have developed a biochip that measures the electrical activities ... data in just one reading than is possible with current ... speed scientific research, which could accelerate drug development for muscle ... crop varieties. , "Instead of doing one experiment ...
Cached Biology News:Buildup of damaged DNA in cells drives aging 2Buildup of damaged DNA in cells drives aging 3Buildup of damaged DNA in cells drives aging 4Long-term cancer risk follows stem cell transplant recipients 2New biochip helps study living cells, may speed drug development 2New biochip helps study living cells, may speed drug development 3
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
...
Biology Products: